Magen E, Komarova I, Magen I, Phirtskhalava S. Case of benralizumab‐induced exacerbations of chronic spontaneous urticaria.
Clin Case Rep 2022;
10:e05930. [PMID:
35765284 PMCID:
PMC9207228 DOI:
10.1002/ccr3.5930]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 03/04/2022] [Accepted: 03/28/2022] [Indexed: 11/11/2022] Open
Abstract
The role of IL‐5 in chronic spontaneous urticarial (CSU) is unclear. It may be that benralizumab is an important bidirectional modifier of CSU; that is, blocking IL‐5 may improve CSU in some patients, but it is possible that it may worsen CSU in others.
The anti‐interleukin‐5 monoclonal IL‐5‐ (IL‐5) receptor‐α antibody benralizumab is currently proposed as one of the drugs for the treatment of patients with severe chronic spontaneous urticaria (CSU). However, it is possible that benralizumab, as a bidirectional modifier of CSU, may lead to exacerbation of CSU in some patients.
Collapse